[go: up one dir, main page]

WO2017163268A3 - A sustained release pharmaceutical dosage form of divalproex - Google Patents

A sustained release pharmaceutical dosage form of divalproex Download PDF

Info

Publication number
WO2017163268A3
WO2017163268A3 PCT/IN2017/050107 IN2017050107W WO2017163268A3 WO 2017163268 A3 WO2017163268 A3 WO 2017163268A3 IN 2017050107 W IN2017050107 W IN 2017050107W WO 2017163268 A3 WO2017163268 A3 WO 2017163268A3
Authority
WO
WIPO (PCT)
Prior art keywords
divalproex
dosage form
sustained release
pharmaceutical dosage
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2017/050107
Other languages
French (fr)
Other versions
WO2017163268A2 (en
Inventor
Vishal SUHAGIYA
T Nathamani
Amol Kulkarni
Shirish Kulkarni
Rajamannar Thennati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2017163268A2 publication Critical patent/WO2017163268A2/en
Publication of WO2017163268A3 publication Critical patent/WO2017163268A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained.
PCT/IN2017/050107 2016-03-23 2017-03-23 A sustained release pharmaceutical dosage form of divalproex Ceased WO2017163268A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621010254 2016-03-23
IN201621010254 2016-03-23

Publications (2)

Publication Number Publication Date
WO2017163268A2 WO2017163268A2 (en) 2017-09-28
WO2017163268A3 true WO2017163268A3 (en) 2018-01-11

Family

ID=59899150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050107 Ceased WO2017163268A2 (en) 2016-03-23 2017-03-23 A sustained release pharmaceutical dosage form of divalproex

Country Status (1)

Country Link
WO (1) WO2017163268A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US20010005512A1 (en) * 1998-12-18 2001-06-28 Anderson William J. Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2008032208A2 (en) * 2006-09-11 2008-03-20 Aurobindo Pharma Limited Extended release formulation of an antiepileptic agent
WO2009008004A2 (en) * 2007-05-23 2009-01-15 Sun Pharmaceutical Industries Limited Sustained release formulations of divalproex sodium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US20010005512A1 (en) * 1998-12-18 2001-06-28 Anderson William J. Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2008032208A2 (en) * 2006-09-11 2008-03-20 Aurobindo Pharma Limited Extended release formulation of an antiepileptic agent
WO2009008004A2 (en) * 2007-05-23 2009-01-15 Sun Pharmaceutical Industries Limited Sustained release formulations of divalproex sodium

Also Published As

Publication number Publication date
WO2017163268A2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
EP4470614A3 (en) Pharmaceutical compositions comprising meloxicam
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
EP4512394A3 (en) Dosage forms and use thereof
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016055797A3 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2017060771A3 (en) Combination therapies for treating cancer
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2018011799A (en) Extended release, abuse deterrent dosage forms.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
MX380070B (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MY195054A (en) Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
WO2017163268A3 (en) A sustained release pharmaceutical dosage form of divalproex
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2